Get started
Author

Philippe P. Van Hootegem

Observed names: P Van Hootegem, P van Hootegem, P. Van Hootegem, Ph Van Hootegem, Philippe P Van Hootegem, Philippe Van Hootegem, Philippe van Hootegem, VAN HOOTEGEM P, Van Hootegem, P., Van Hootegem, Philippe
ORCID: 0000-0001-8258-6225
Observed ORCID: 0000-0001-8258-6225
OpenAlex ID: A5104008169
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
2008 · Geert D'Haens, Filip Baert, et al. · The Lancet · 1,246
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
2018 · Geert D’Haens, Severine Vermeire, et al. · Gastroenterology · 310
Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy
2013 · Martine De Vos, Edouard J. Louis, et al. · Inflammatory Bowel Diseases · 201
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study
2019 · Claire Liefferinckx, Bram Verstockt, et al. · Journal of Crohn s and Colitis · 124
PDF
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
2023 · Edouard Louis, Matthieu Resche-Rigon, et al. · The Lancet. Gastroenterology & hepatology · 114
Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study
2018 · Séverine Vermeire, François D'heygere, et al. · Patient Preference and Adherence · 60
PDF
Serum Bilirubins in Hepatobiliary Disease: Comparison With Other Liver Function Tests and Changes in the Postobstructive Period
1985 · Philippe Van Hootegem, Johan Fevery, et al. · Hepatology · 37
PDF
Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort
2018 · Peter Bossuyt, Filip Baert, et al. · Inflammatory Bowel Diseases · 33
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease
2020 · Peter Bossuyt, Erwin Dreesen, et al. · Clinical Gastroenterology and Hepatology · 27
PDF
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial
2021 · David Laharie, Geert D’Haens, et al. · Clinical Gastroenterology and Hepatology · 23
692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX)
2016 · Geert R. D'Haens, Severine Vermeire, et al. · Gastroenterology · 22
Pneumatosis cystoides intestinalis, four cases of a rare disease.
2002 · R J M W Rennenberg, G H Koek, et al. · PubMed · 22
Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response
2021 · An Outtier, Lucas Wauters, et al. · GastroHep · 21
PDF
Jejuno-ileal diverticulosis : a review of literature.
2018 · A-S Ceuppens, S Dhont, et al. · PubMed · 15
Pancreatitis-Induced Extrahepatic Portal Vein Stenosis Treated by Percutaneous Transhepatic Stent Placement: a Case Report
2003 · G. Maleux, J. Vaninbroukx, et al. · CardioVascular and Interventional Radiology · 15
Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE).
2020 · C Reenaers, A Cremer, et al. · PubMed · 13
Four patients with Amanita Phalloides poisoning.
2014 · S Vanooteghem, J Arts, et al. · PubMed · 12
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
2020 · A Cremer, T Lobaton, et al. · Journal of Crohn s and Colitis · 10
PDF
Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
2015 · S Vermeire, E Louis, et al. · PubMed · 8
PDF
COVID‐19 and digestive health: Implications for prevention, care and the use of COVID‐19 vaccines in vulnerable patients
2021 · Markus Peck‐Radosavljevic, Patrizia Burra, et al. · United European Gastroenterology Journal · 7
PDF
Is Crohn’s Disease a Rightly Used Eponym?
2019 · Philippe Van Hootegem, Simon Travis · Journal of Crohn s and Colitis · 5
PDF
Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).
2018 · D Franchimont, M Ferrante, et al. · PubMed · 5
P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study
2022 · D Alsoud, D Franchimont, et al. · Journal of Crohn s and Colitis · 3
The “Fonds Georges Brohée” : a longstanding Belgian national initiative to stimulate research in hepatogastroenterology
2021 · I Borbath, R Fiasse, et al. · Acta gastro-enterologica belgica · 3
PDF
COVID‐19 and digestive health
2020 · Markus Peck‐Radosavljevic, Silvio Danese, et al. · United European Gastroenterology Journal · 3
PDF
Works count: 57
Citation count: 2,352
H-index: 15
I10-index: 18
Year
Topic
Type